Altimmune (NYSE:ALT) is scheduled to release its earnings data before the market opens on Thursday, November 14th. Analysts expect Altimmune to post earnings of ($0.19) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Altimmune (NYSE:ALT) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.01). The company had revenue of $1.63 million for the quarter, compared to the consensus estimate of $2.41 million.

ALT opened at $1.78 on Tuesday. The firm has a 50-day moving average of $1.96 and a 200 day moving average of $2.27. Altimmune has a fifty-two week low of $1.70 and a fifty-two week high of $5.94.

Separately, Roth Capital restated a “buy” rating on shares of Altimmune in a research report on Friday, July 19th.

Altimmune Company Profile

Altimmune, Inc, a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials.

Recommended Story: Producer Price Index (PPI)

Earnings History for Altimmune (NYSE:ALT)

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with's FREE daily email newsletter.